Free Trial

Tvardi Therapeutics (TVRD) Competitors

Tvardi Therapeutics logo
$5.00 -0.16 (-3.10%)
As of 03:39 PM Eastern

TVRD vs. CRBU, OGI, LFCR, ALTS, AVIR, SGMT, CRBP, HRTX, ENTA, and RNAC

Should you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include Caribou Biosciences (CRBU), Organigram Global (OGI), Lifecore Biomedical (LFCR), ALT5 Sigma (ALTS), Atea Pharmaceuticals (AVIR), Sagimet Biosciences (SGMT), Corbus Pharmaceuticals (CRBP), Heron Therapeutics (HRTX), Enanta Pharmaceuticals (ENTA), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry.

Tvardi Therapeutics vs. Its Competitors

Caribou Biosciences (NASDAQ:CRBU) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Caribou Biosciences currently has a consensus price target of $6.67, indicating a potential upside of 167.31%. Tvardi Therapeutics has a consensus price target of $55.50, indicating a potential upside of 1,010.00%. Given Tvardi Therapeutics' higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Caribou Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Tvardi Therapeutics
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

Caribou Biosciences has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 8.3% of Caribou Biosciences shares are owned by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Tvardi Therapeutics and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.17 beat Tvardi Therapeutics' score of 0.46 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Caribou Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tvardi Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tvardi Therapeutics has a net margin of -678.79% compared to Caribou Biosciences' net margin of -1,800.93%. Caribou Biosciences' return on equity of -62.35% beat Tvardi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Caribou Biosciences-1,800.93% -62.35% -49.65%
Tvardi Therapeutics -678.79%-565.83%-66.71%

Tvardi Therapeutics has lower revenue, but higher earnings than Caribou Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caribou Biosciences$9.12M25.46-$149.10M-$1.78-1.40
Tvardi Therapeutics$7.14M6.57-$70.87MN/AN/A

Summary

Caribou Biosciences beats Tvardi Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVRD vs. The Competition

MetricTvardi TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$46.90M$3.42B$6.16B$10.78B
Dividend YieldN/A2.26%5.71%4.83%
P/E RatioN/A23.2829.7128.64
Price / Sales6.57270.86500.63191.51
Price / CashN/A45.1236.6160.64
Price / Book-1.6610.4012.026.61
Net Income-$70.87M-$52.62M$3.32B$276.75M
7 Day Performance-24.01%2.06%1.57%2.09%
1 Month Performance-86.50%10.79%6.19%2.67%
1 Year PerformanceN/A13.69%61.23%33.58%

Tvardi Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVRD
Tvardi Therapeutics
2.7462 of 5 stars
$5.00
-3.1%
$55.50
+1,010.0%
N/A$46.90M$7.14M0.0080High Trading Volume
CRBU
Caribou Biosciences
2.8606 of 5 stars
$2.63
-1.5%
$6.67
+153.5%
+30.2%$244.91M$9.99M-1.48100Positive News
Analyst Forecast
Gap Up
OGI
Organigram Global
0.8722 of 5 stars
$1.82
-3.7%
N/A-4.9%$244.72M$117.47M0.00860
LFCR
Lifecore Biomedical
1.1585 of 5 stars
$6.49
-0.6%
$8.00
+23.3%
+28.2%$243.15M$128.87M-4.95690
ALTS
ALT5 Sigma
0.3242 of 5 stars
$1.95
-11.0%
N/A-18.5%$243.02M$12.53M0.00170Gap Up
AVIR
Atea Pharmaceuticals
1.8054 of 5 stars
$3.06
-1.9%
$6.00
+96.1%
-8.3%$242.84MN/A0.0070Analyst Forecast
SGMT
Sagimet Biosciences
3.1855 of 5 stars
$7.36
-2.5%
$25.67
+248.7%
+29.7%$239.36M$2M-4.028Gap Up
CRBP
Corbus Pharmaceuticals
4.2299 of 5 stars
$19.32
+1.4%
$45.43
+135.1%
+4.8%$236.77MN/A-4.0640Analyst Forecast
Analyst Revision
High Trading Volume
HRTX
Heron Therapeutics
3.951 of 5 stars
$1.29
-0.8%
$4.50
+248.8%
-33.9%$236.48M$144.29M-64.50300
ENTA
Enanta Pharmaceuticals
4.0211 of 5 stars
$11.01
-3.3%
$20.83
+89.2%
-16.3%$235.37M$67.64M-2.55160Analyst Forecast
RNAC
Cartesian Therapeutics
1.9271 of 5 stars
$9.01
-4.4%
$40.00
+344.0%
-59.4%$234.28M$38.91M0.0064Analyst Forecast

Related Companies and Tools


This page (NASDAQ:TVRD) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners